+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)

  • ID: 4720463
  • Report
  • November 2018
  • Region: Global
  • 52 Pages
  • GlobalData
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Afimmune
  • BMS
  • DeuteRx
  • HighTide Biopharma
  • Naia
  • Second Genome
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)

Summary

"Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)", briefings contain evaluations of ongoing development activities within the Non-Alcoholic Steatohepatitis (NASH) disease market, together with analysis of current & potential future product positioning.

Key Highlights from the report -
  • Phase II NCT02787304 trial has been discontinued, and the future of SHP626 (volixibat) in NASH is currently uncertain

  • Topline results for Phase IIb NATIVE trial of lanifibranor in NASH are currently expected in H1 2020 (delayed from the original schedule of mid-2018 due to slow patient enrollment)

  • Medicinova will likely initiate a Phase IIb trial for MN-001 with biopsy-based endpoints, which could begin at any time



The report comprises three sections -

Executive Summary
  • Contains analysis of key market events that have occurred during the previous month and which have impacted the NASH landscape.


Landscape Updates
  • ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.

  • Timeline forecasts for each approved product’s lifecycle management initiatives.

  • ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline therapies.



Pipeline Landscape
  • An overview of pipeline candidates, containing snapshots of current development status.

  • Expected drug-specific events & milestones until YE 2020.



Appendix
  • Current early stage RA pipeline & candidate ‘Watch List’.

  • Timeline assumptions, including standard assumptions & drug-specific assumptions.



Scope
  • The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)

  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix

  • Forecasts are presented in pipeline forecast figures & detailed tables

  • ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.



Reasons to Buy
  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher

  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market

  • Reviews ongoing lifecycle management strategies for existing players in the market

  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Afimmune
  • BMS
  • DeuteRx
  • HighTide Biopharma
  • Naia
  • Second Genome
Introduction to Sociable Pharma’s ‘Competitor Landscape’
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Key Competitor Market Entry Strategies
Lifecycle Development
Key Competitor ‘Direction of Travel’
Pipeline Landscape
Pipeline Summary
Appendix
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Afimmune

  • Akarna Therapeutics

  • Akero Therapeutics

  • Albireo

  • Allergan

  • Allergan (acquired from

  • Ardelyx

  • Arisaph

  • AstraZeneca

  • BHV Pharma Inc

  • Bird Rock Bio/Janssen

  • BMS

  • Boehringer Ingelheim

  • Can-Fite BioPharma

  • Celgene

  • Cempra

  • Cerenis Therapeutics

  • ChemomAb

  • Cirius Therapeutics

  • CohBar

  • ConSynance Therapeutics

  • CymaBay Therapeutics

  • DeuteRx

  • Dr. Falk Pharma GmbH

  • DURECT Corporation

  • Eli Lilly

  • Enanta

  • Galectin Therapeutics

  • Galmed

  • Gemcabene

  • Genfit

  • Gilead

  • GRI Bio

  • HighTide Biopharma

  • Immune Pharmaceuticals Inc.

  • Immuron

  • Intercept

  • INVENT Pharmaceuticals

  • Inventiva

  • Ionis Pharma-ceuticals

  • Janssen

  • Madrigal

  • MediciNova

  • Metacrine

  • Mitsubishi Tanabe

  • Naia

  • NGM Biopharmaceuticals

  • Nitto Denko

  • NorthSea Therapeutics

  • Novartis

  • Novo Nordisk

  • NuSirt BioPharma

  • Oramed

  • Pfizer

  • Poxel

  • Sanofi

  • Second Genome

  • Shire

  • Sinew Pharma

  • Sucampo Pharmaceuticals

  • Synairgen

  • Taiwan Pharmaceuticals

  • Teva

  • Tiziana Life Sciences

  • Valbiotis

  • Viking Therapeutics

  • Virobay

  • Zafgen

  • Zydus Discovery

Note: Product cover images may vary from those shown